We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
+12.37%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$310M
AUM Growth
-$220K
Cap. Flow
-$11.6M
Cap. Flow %
-3.74%
Top 10 Hldgs %
66.11%
Holding
86
New
13
Increased
6
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
TEM
Tempus AI
TEM
+$4.6M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$3.68M
3
FLD
Fold Holdings
FLD
+$3.68M
4
STWD icon
Starwood Property Trust
STWD
+$2.55M
5
BMEA icon
Biomea Fusion
BMEA
+$2.5M

Top Sells

Rank Stock Value
1
TQQQ icon
ProShares UltraPro QQQ
TQQQ
+$10M
2
CMPS
Compass Pathways
CMPS
+$3.41M
3
ETWO
E2open Parent Holdings
ETWO
+$3.3M
4
TNGX icon
Tango Therapeutics
TNGX
+$3.23M
5
CNDT icon
Conduent
CNDT
+$2.91M

Sector Composition

Rank Sector Weight
1 Healthcare 51.14%
2 Financials 31.24%
3 Technology 10.9%
4 Consumer Discretionary 5.02%
5 Real Estate 0.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NCDL icon
1
Nuveen Churchill Direct Lending
NCDL
$624M
$65.4M 21.11%
4,039,553
– –
OBDC icon
2
Blue Owl Capital
OBDC
$5.47B
$29.3M 9.46%
2,045,070
– –
CGEM icon
3
Cullinan Oncology
CGEM
$1.07B
$18M 5.8%
2,385,972
-50,000
-2% -$402K
EVCM icon
4
EverCommerce
EVCM
$2.12B
$17.2M 5.56%
1,641,929
– –
TRML
5
DELISTED
Tourmaline Bio
TRML
$15.9M 5.15%
997,107
-40,000
-4% -$648K
LRMR icon
6
Larimar Therapeutics
LRMR
$398M
$14.2M 4.6%
4,928,040
+150,000
+3% +$347K
ENGN icon
7
enGene Therapeutics
ENGN
$118M
$13.6M 4.38%
3,728,106
+448,728
+14% +$1.68M
CNDT icon
8
Conduent
CNDT
$251M
$11.8M 3.8%
4,456,848
-1,240,602
-22% -$2.91M
SGMT icon
9
Sagimet Biosciences
SGMT
$449M
$10.1M 3.27%
1,328,351
– –
RARE icon
10
Ultragenyx Pharmaceutical
RARE
$2.56B
$9.28M 3%
255,238
+102,000
+67% +$3.68M
HLLY icon
11
Holley
HLLY
$336M
$8.22M 2.65%
4,112,361
-1,205,679
-23% -$2.56M
CVEO icon
12
Civeo
CVEO
$376M
$7.33M 2.37%
317,411
-30,815
-9% -$652K
CMPX icon
13
Compass Therapeutics
CMPX
$367M
$6.74M 2.17%
2,591,525
-363,187
-12% -$749K
IRON icon
14
Disc Medicine
IRON
$2.85B
$6.47M 2.09%
122,260
-18,000
-13% -$845K
IMA
15
ImageneBio Inc
IMA
$65.5M
$5.48M 1.77%
340,927
– –
EYPT icon
16
EyePoint Inc
EYPT
$1B
$5.29M 1.71%
562,594
-235,000
-29% -$1.62M
TEM
17
Tempus AI
TEM
$7.72B
$5.09M 1.64%
+80,167
New +$4.6M
CNTX icon
18
Context Therapeutics
CNTX
$54.3M
$4.85M 1.57%
7,407,906
+40,000
+0.5% +$28.8K
RPTX
19
DELISTED
Repare Therapeutics
RPTX
$4.79M 1.54%
3,443,659
– –
MLYS icon
20
Mineralys Therapeutics
MLYS
$2.38B
$4.55M 1.47%
335,944
+129,648
+63% +$1.88M
CNTA
21
DELISTED
Centessa Pharmaceuticals
CNTA
$4.34M 1.4%
330,600
+15,600
+5% +$198K
TNGX icon
22
Tango Therapeutics
TNGX
$4.34B
$4.17M 1.35%
814,416
-1,307,236
-62% -$3.23M
ELDN icon
23
Eledon Pharmaceuticals
ELDN
$262M
$3.6M 1.16%
1,329,912
-490,000
-27% -$1.47M
PLRX icon
24
Pliant Therapeutics
PLRX
$66.3M
$3.44M 1.11%
2,969,199
– –
AQST icon
25
Aquestive Therapeutics
AQST
$472M
$3.05M 0.98%
920,000
– –
1
2 3 4

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $372M AUM 50.62% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return

Blue Owl Capital Holdings's Q2 2025 Portfolio in Review

As of Q2 2025, Blue Owl Capital Holdings held 86 positions worth $310M, down 0.07% from $310M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Blue Owl Capital Holdings withdrew a net $11.6M in Q2 2025, closing 14 positions and reducing 14 holdings. Its most notable exit was ProShares UltraPro QQQ, an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 44% a quarter earlier, followed by Financials and Technology.

Against the trend, Blue Owl Capital Holdings opened a new position in Tempus AI worth $5.09M.

  • Blue Owl Capital Holdings's largest Q2 2025 buy was Tempus AI: 80,167 shares worth $5.09M.
  • Blue Owl Capital Holdings added most to Ultragenyx Pharmaceutical in Q2 2025, an estimated $3.68M increase.
  • Blue Owl Capital Holdings's biggest Q2 2025 reduction was Compass Pathways, cutting an estimated $3.41M.
  • Blue Owl Capital Holdings fully exited ProShares UltraPro QQQ in Q2 2025, selling an estimated $10M.
  • Blue Owl Capital Holdings's ten largest holdings make up 66% of its $310M portfolio in Q2 2025.
  • Blue Owl Capital Holdings opened 13 new positions and closed 14 in Q2 2025.
  • Blue Owl Capital Holdings's portfolio value fell 0.07% quarter-over-quarter to $310M.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2025, filed 11 Aug 2025.